FDA's new drug safety panel under fire

Senate Finance Committee Chairman Charles E. Grassley, R-Iowa, says the FDA's new drug safety panel is not an improvement on the current system and represents "nothing more than the status quo." Grassley's criticism was echoed by FDA whistle-blower David Graham, who said the panel is "severely biased in favor of industry." Congress and other administration officials are considering alternative proposals to address drug safety.

View Full Article in:

Washington Post (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Actuary
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
MetLife
Bridgewater, NJ